Mayansh Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
- Paid Up Capital ₹ 0.15 M
- Company Age 15 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.92 M
- Revenue Growth 6.77%
- Profit Growth 23.56%
- Ebitda 30.93%
- Net Worth 49.06%
- Total Assets -20.29%
About Mayansh Biotech
Mayansh Biotech Private Limited (MBPL) is a Private Limited Indian Non-Government Company incorporated in India on 10 December 2009 and has a history of 15 years and two months. Its registered office is in Gurugram, Haryana, India.
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.15 M.
The company currently has active open charges totaling ₹0.92 M.
Manoj Sharma and Vipula Sharma serve as directors at the Company.
Company Details
-
Location
Gurugram, Haryana, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U24232HR2009PTC039796
-
Company No.
039796
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
10 Dec 2009
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Mayansh Biotech?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manoj Sharma
|
Director | 18-Feb-2014 | Current |
|
Vipula Sharma
|
Director | 10-Dec-2009 | Current |
Financial Performance of Mayansh Biotech.
Mayansh Biotech Private Limited, for the financial year ended 2020, experienced modest growth in revenue, with a 6.77% increase. The company also saw a substantial improvement in profitability, with a 23.56% increase in profit. The company's net worth Soared by an impressive increase of 49.06%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mayansh Biotech?
In 2020, Mayansh Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Nichichem Lifescience Private LimitedManoj Sharma and Vipula Sharma are mutual person
Charges (Loans)
₹0.92 M
₹0
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 0.09 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 18 Nov 2020 | Hdfc Bank Limited | ₹0.92 M | Open |
How Many Employees Work at Mayansh Biotech?
Unlock and access historical data on people associated with Mayansh Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mayansh Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mayansh Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
